Screener
Sarepta Therapeutics, Inc. SRPT Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
FAQ
- What is Sarepta Therapeutics, Inc.'s deferred revenue?
- Sarepta Therapeutics, Inc. (SRPT) reported deferred revenue of $110.13M in Q2 2026.
- How has Sarepta Therapeutics, Inc.'s deferred revenue changed year-over-year?
- Sarepta Therapeutics, Inc.'s deferred revenue decreased by 72.1% year-over-year, from $395.43M to $110.13M.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s deferred revenue?
- Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s deferred revenue has grown at a 37.8% compound annual growth rate (CAGR), from $89.24M to $443.4M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Sarepta Therapeutics, Inc.'s deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude